title: Topical therapy for mucosal yeast infections.
abstract: Mucosal yeast infection is best understood as a consequence of compromised mucosal cell-mediated and innate immunity. Defense against oral candidiasis is dominantly cell mediated. The innate immune system may play the main role in regulating vulvovaginal yeast infection. Conditions that compromise cell-mediated immunity such as leukemia, severe illness and HIV infection must be considered as predisposing factors for recurrent oral candidiasis. Compromise of vaginal innate immunity due to mucosal allergy or due to a genetic defect such as mannose-binding lectin deficiency contributes to chronic vulvovaginal yeast infection. Treatment of cofactors must be considered in order to achieve control in recurrent mucosal yeast infection.
authors.affiliation: Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
authors.forename: Paul R
authors.initials: PR
authors.lastname: Summers
mesh_terms: D000282:Administration, Intravaginal; D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000209:etiology; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D052016:Mucositis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012008:Recurrence; D012307:Risk Factors; D017444:Skin Diseases, Papulosquamous / Q000150:complications
chemical_list: D000935:Antifungal Agents